Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Plc Glaxosmithkline currently holds 732,583 shares of NUPATHE INC. (PATH), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Plc Glaxosmithkline has been a net seller of PATH stock. They have purchased $1.6B and sold $2.6B worth of shares.
Plc Glaxosmithkline's most recent insider trade was on Jul 2, 2021, when they sold 635,646 shares at $0.00 per share.
Plc Glaxosmithkline serves as Executive at NUPATHE INC. (PATH). They have executed 135 insider transactions totaling $4.2B over their tenure at the company.
Plc Glaxosmithkline holds the position of Executive at NUPATHE INC., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 18 years and currently hold a stake valued at $0.
Plc Glaxosmithkline has shown a selling trading pattern, with $1.6B in total purchases and $2.6B in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Plc Glaxosmithkline was on May 20, 2021, when they sold $392.1M worth of INVA shares. This transaction involved 32,005,260 shares at $12.25 per share.
Plc Glaxosmithkline currently owns 732,583 shares of NUPATHE INC. (PATH), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Plc Glaxosmithkline's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Plc Glaxosmithkline has 135 Form 4 filings on record as an insider at NUPATHE INC..
Set alerts for Plc Glaxosmithkline and 40,000+ other insiders.